K.L. Mettinger - Concepedia

Author

K.L. Mettinger

Also Known As

K L Mettinger, K Mettinger, K. L. Mettinger, K. Mettinger, K.L. Mettinger, Karl L. Mettinger, Karl Mettinger, Mettinger, K

Publications

2.1K

Citations

H-Index

Concepts

All Affiliations

Karolinska University Hospital Karolinska Institutet Oncolytics Biotech (Canada)Sarah Cannon Royal Marsden Hospital

About

K.L. Mettinger is an author at Karolinska University Hospital specializing in medicine, pathology, and thrombosis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	17	949
2	Public Health	5	5	397
3	Health Sciences	4	4	96
4	Epidemiology	3	3	126
5	Emergency Medicine	1	1	41

K.L. Mettinger

Publications

1.8K

Citations

H-Index

Page 1

	Year	Citations
Fibromuscular dysplasia and the brain. I. Observations on angiographic, clinical and genetic characteristics. K.L. Mettinger, K. Ericson Stroke Affected Cervical ArteryVascular MalformationPathologyCerebrovascular DiseaseGenetic Characteristics	1982	256
Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies Eleni Karapanagiotou, Victoria Roulstone, Katie Twigger, Clinical Cancer Research	2012	182
Multicenter trial of low‐dose paclitaxel in patients with advanced AIDS‐related Kaposi sarcoma Anil Tulpule, Jerome E. Groopman, M. Wayne Saville, Cancer	2002	158
Intravenous administration of Reolysin®, a live replication competent RNA virus is safe in patients with advanced solid tumors R. Gollamudi, Mohammad H. Ghalib, Kavita Desai, Investigational New Drugs Viral ReplicationMolecular VirologyIntravenous AdministrationMedicinePathology	2009	150
REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer Charles Comins, James Spicer, Andrew Protheroe, Clinical Cancer Research	2010	135
A Phase I Study of the Combination of Intravenous Reovirus Type 3 Dearing and Gemcitabine in Patients with Advanced Cancer Martijn P. Lolkema, Hendrik‐Tobias Arkenau, Kevin J. Harrington, Clinical Cancer Research	2010	120
NORMAL SERUM-CHOLESTEROL BUT LOW H.D.L.-CHOLESTEROL CONCENTRATION IN YOUNG PATIENTS WITH ISCHÆMIC CEREBROVASCULAR DISEASE Stephan Rössner, K.L. Mettinger, K.G. Kjellin, The Lancet ThrombosisVascular DiseaseCardiovascular DiseaseMedicineHyperlipidemia	1978	113
The protective role of the immunomodulator AS101 against chemotherapy-induced alopecia studies on human and animal models Benjamin Sredni, Ren-He Xu, Michael Albeck, International Journal of Cancer	1996	85
Phase II Trial of Oral Rubitecan in Previously Treated Pancreatic Cancer Patients Howard A. Burris, Saul E. Rivkin, Robert E. Reynolds, The Oncologist	2005	67
Factor VIII related antigen, antithrombin III, spontaneous platelet aggregation and plasminogen activator in ischemic cerebrovascular disease K.L. Mettinger, Dag Nyman, K.G. Kjellin, Journal of the Neurological Sciences PathologyInflammationThrombosisSpontaneous Platelet AggregationStroke	1979	59

Page 1